Intensified CHOP of 12-weeks duration plus G-CSF as compared with standard CHOP of 24-weeks duration for patients with intermediate prognosis non-Hodgkin's lymphoma
| ISRCTN | ISRCTN11397785 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11397785 |
| Secondary identifying numbers | Ho26 |
- Submission date
- 20/12/2005
- Registration date
- 20/12/2005
- Last edited
- 09/11/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr L F Verdonck
Scientific
Scientific
University Medical Centre Utrecht
Department of Haematology
P.O. Box 85500
Utrecht
3508 GA
Netherlands
| Phone | +31 (0)30 250 7230 |
|---|---|
| l.f.verdonck@azu.nl |
Study information
| Study design | Randomised, placebo controlled, parallel group, multicentre trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Intensified CHOP of 12-weeks duration plus G-CSF as compared with standard CHOP of 24-weeks duration for patients with intermediate prognosis non-Hodgkin's lymphoma |
| Study acronym | HOVON 26 NHL |
| Study objectives | The hypothesis to be tested is that the outcome in arm B is better than in arm A. |
| Ethics approval(s) | Ethics approval received from the local medical ethics committee |
| Health condition(s) or problem(s) studied | Non Hodgkin's lymphoma (NHL) |
| Intervention | Patients will be randomised between: Arm A: Three courses of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every three weeks. Arm B: Three courses of intensified CHOP every two weeks plus Granulocyte-Colony Stimulating Factor (G-CSF). Patients with less than Partial Response (PR) will go off protocol. Patients in PR or Complete Response (CR) will proceed to another five courses of standard CHOP or another three courses of intensified CHOP plus G-CSF. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and Granulocyte-Colony Stimulating Factor (G-CSF). |
| Primary outcome measure | CR rate and overall survival. |
| Secondary outcome measures | 1. Disease-free survival 2. Relapse rate 3. Assessment of value of risk factors at diagnosis in relation to dose intensity of the treatment 4. Morbidity, number of days in hospital, treatment-related mortality, duration of leucopenia and other aspects in relation to dose intensity |
| Overall study start date | 11/11/1994 |
| Completion date | 01/04/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 513 |
| Total final enrolment | 477 |
| Key inclusion criteria | 1. Previously untreated patients with a primary Non Hodgkins Lymphoma (NHL) of intermediate or high grade malignancy according to the Working Formulation (group D, E, F, G, H) 2. Belonging to the intermediate risk group: a. stage II, Lactate Dehydrogenase (LDH) greater than or equal to 1.5 x normal b. stage III, LDH greater than 1.5 x normal c. stage IV, LDH less than 1.5 x normal 3. Age greater than or equal to 15, or less than or equal to 65 years |
| Key exclusion criteria | 1. Patients with prior malignancies, except stage one cervix carcinoma and basocellular carcinoma 2. Patients with severe cardiac (means severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%) pulmonary, neurologic or metabolic disease. 3. Inadequate liver or renal function i.e. serum creatinine or bilirubin greater than 25 x the upper normal value, except when related to the lymphoma 4. Human Immunodeficiency Virus (HIV) positivity 5. Inability to give informed consent 6. Involvement of the central nervous system by the NHL |
| Date of first enrolment | 11/11/1994 |
| Date of final enrolment | 01/04/2004 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
University Medical Centre Utrecht
Utrecht
3508 GA
Netherlands
3508 GA
Netherlands
Sponsor information
Daniel den Hoed Kliniek (Erasmus Medical Centre) (The Netherlands)
Hospital/treatment centre
Hospital/treatment centre
P.O. Box 5201
Rotterdam
3008 AE
Netherlands
| Phone | +31 (0)10 439 1568 |
|---|---|
| hdc@erasmusmc.nl | |
| Website | http://www.erasmusmc.nl/ |
"ROR" |
https://ror.org/018906e22 |
Funders
Funder type
Research organisation
Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)
No information available
The National Cancer Fund (Koningin Wilhelmina Fonds [KWF]) (The Netherlands)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 01/04/2007 | Yes | No |
Editorial Notes
09/11/2022: Total final enrolment added.
